A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC
Journal of Thoracic Oncology · 2024-03 · 19 (3) · 465-475
DOI: 10.1016/j.jtho.2023.10.014 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Thoracic Oncology, 2024-03. Verfasst von Lei Wang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
INTRODUCTION: This study (HARMONi-5) aimed to evaluate the safety and efficacy of ivonescimab (a bispecific antibody against programmed cell death protein 1 and vascular endothelial growth factor) as first- or second-line monotherapy in patients with advanced immunotherapy-naive NSCLC. METHODS: Eligible patients received intravenous ivonescimab 10 mg/kg every 3 weeks (Q3W), 20 mg/kg every 2 weeks (Q2W), 20 mg/kg Q3W, or 30 mg/kg Q3W. The primary end points were safety and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: At data cutoff (October 5, 2022), 108 patients were enrolled and received ivonescimab. Programmed death ligand-1 tumor proportion score (TPS) was greater than or equal to 1% in 74 patients (68.5%), including 35 (32.4%) with TPS greater than or equal to 50%. The median follow-up was 10.4 months (range: 8.4-10.9 mo). For all patients, ORR and disease control rate were 39.8% and 86.1%, respectively. ORR by TPS was 14.7%, 51.4%, and 57.1% in patients with TPS less than 1%, greater than or equal to 1%, and greater than or equal to 50%, respectively. In the 67 programmed death ligand-1-positive patients receiving first-line ivonescimab, the ORR was 33.3%, 52.6%, 60.0%, and 75.0% at the doses of 10 mg/kg Q3W, 20 mg/kg Q2W, 20 mg/kg Q3W, and 30 mg/kg Q3W, respectively. Grade greater than or equal to 3 treatment-related adverse events (TRAEs) were observed in 24 patients (22.2%). TRAEs leading to treatment discontinuation occurred in one patient (0.9%). TRAEs leading to death occurred in three patients (2.8%) with squamous NSCLC. The occurrence of grade greater than or equal to 3 TRAEs and grade greater than or equal to 3 bleeding events in squamous versus nonsquamous NSCLC patients was 25.5% versus 18.9% and 0.0% versus 1.9%, respectively. CONCLUSIONS: Ivonescimab monotherapy was well tolerated and found to have a promising efficacy in patients with advanced or metastatic NSCLC. CLINICALTRIALS: gov identifier: NCT04900363.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Department, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
- The First Department of Thoracic Medicine, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China.
- Department of Respiratory Oncology, Anhui Provincial Cancer Hospital, Hefei, People's Republic of China.
- Department of Medical Oncology, Cancer Hospital of Sichuan Province, Chengdu, People's Republic of China.
- Department of Thoracic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, People's Republic of China.
- Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, People's Republic of China.
Zitieren
APA
Wang, L., Luo, Y., Ren, S., Zhang, Z., Xiong, A., Su, C., Zhou, J., Yu, X., Hu, Y., Zhang, X., Dong, X., Meng, S., Wu, F., Hou, X., Dai, Y., Song, W., Li, B., Wang, Z. M., Xia, Y., & Zhou, C. (2024). A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC. Journal of Thoracic Oncology, 19(3), 465-475. https://doi.org/10.1016/j.jtho.2023.10.014
Vancouver
Wang L, Luo Y, Ren S, Zhang Z, Xiong A, Su C, et al. A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC. Journal of Thoracic Oncology. 2024;19(3):465-475. doi:10.1016/j.jtho.2023.10.014
BibTeX
@article{Wang2024,
author = {Wang, Lei and Luo, Yongzhong and Ren, Shengxiang and Zhang, Zhihong and Xiong, Anwen and Su, Chunxia and Zhou, Jin and Yu, Xinmin and Hu, Yanping and Zhang, Xiaodong and Dong, Xiaorong and Meng, Shuyan and Wu, Fengying and Hou, Xiaoming and Dai, Yuanrong and Song, Weifeng and Li, Baiyong and Wang, Zhongmin Maxwell and Xia, Yu and Zhou, Caicun},
title = {A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC},
journal = {Journal of Thoracic Oncology},
year = {2024},
volume = {19},
number = {3},
pages = {465--475},
doi = {10.1016/j.jtho.2023.10.014}
}
EUVIMED